Abstract: The present invention relates, in part, to agents that bind CD8 and their use as therapeutic and diagnostic agents. The present invention further relates to pharmaceutical compositions comprising the CD8 binding agents and their use in the treatment of various diseases, including, for example, cancers.

Abstract: The invention pertains to inhibitors of various kinases (e.g. S/T kinases, Tyr kinases, etc.), which inhibitors are previously known as cyclin dependent kinase inhibitors (CDKs). As described herein, the inhibitors of this invention are capable of inhibiting various wild-type and mutant form kinases, including drug resistant forms of mutant kinases. Thus the subject kinase inhibitors are useful in treating a wide range of diseases/conditions associated with abnormal functions/excessive activities of the target kinases, including mutant kinases. The invention further provides methods for treating cancers, tumors and patients which are resistant or refractory to other therapeutic agents. Pharmaceutical compositions and packaged pharmaceuticals with instructions of these inhibitors, and methods of using these inhibitors are also provided.

Abstract: The invention provides compositions and methods for isolating ligand binding polypeptides for a user-specified ligand, and for isolating small molecule ligands for a user-specified target polypeptide using an improved class of hybrid ligand compounds.

Abstract: The invention provides compositions and methods for isolating ligand binding polypeptides for a user-specified ligand, and for isolating small molecule ligands for a user-specified target polypeptide using an improved class of hybrid ligand compounds.

Abstract: The invention provides compositions and methods for isolating ligand binding polypeptides for a user-specified ligand, and for isolating small molecule ligands for a user-specified target polypeptide using an improved class of hybrid ligand compounds.

Abstract: This present invention concerns polypeptide molecules comprising human p53 response protein PIGI-1.

Abstract: Novel human and mouse NF2 transcript isoforms and proteins encoded thereby, are disclosed. The isoforms are found in a variety of tissue and tumor types and represent differential processing of genomic DNA sequences, at the level of transcription, resulting in variant proteins. The isoforms provide useful tools for the analysis of the normal function of tumor suppressor factors, such as the merlin protein, and also provide useful markers for the detection of NF2 disease.

Abstract: Methods of treating p53-related tumors by administering (1) a modulator of IGF-BP3, wherein the modulator upregulates IGF-BP3 expression or activity, (2) IGF-BP3 itself, or (3) an expression vector comprising a nucleotide sequence encoding IGF-BP3. In the latter method, the IGF-BP3 nucleotide sequence may also be operatively linked to an inducible promoter or enhancer, wherein the method further comprises administering an inducer capable of initiating or upregulating expression of the protein. Furthermore, any of the foregoing methods may include as an additional step administration of a cytotoxic agent. These methods are specific examples of a broader method: treatment of p53-related tumors by inhibiting the binding of IGF to IGFR.

Abstract: Nucleic acid sequences, particularly DNA sequences, coding for all or part of p53 response protein PIGI-1, expression vectors containing the DNA sequences, host cells containing the expression vectors, and methods utilizing these materials are disclosed. The invention also concerns polypeptide molecules comprising all or part of p53 response protein PIGI-1, and methods for producing these polypeptide molecules.

Abstract: Novel human and mouse NF2 transcript isoforms and proteins encoded thereby, are disclosed. The isoforms are found in a variety of tissue and tumor types and represent differential processing of genomic DNA sequences, at the level of transcription, resulting in variant proteins. The isoforms provide useful tools for the analysis of the normal function of tumor suppressor factors, such as the merlin protein, and also provide useful markers for the detection of NF2 disease.